Sunday, 5 September 2021 (YJC)_ Iran started the third phase of the human trial of its homemade coronavirus vaccine.
The Vice President for Research and Technology Affairs at the parent Razi Vaccine and Serum Research Institute and spokesman for the project Mohammad Hossein Fallah Mehrabadi announced on Sunday that Iran has started the third phase of the human trial of its second domestic coronavirus vaccine, Razi Cov Pars.
“The third phase will be carried out in Tehran and Alborz provinces with the participation of some 40,000 volunteers,” he said while adding that people aged 18 or above, who have not contracted the coronavirus, are eligible to take part in the trial.
Fallah Mehrabadi also said “Last month, Razi Vaccine and Serum Research Institute has produced 400,000 doses of the vaccine.”
Razi Cov Pars is a recombinant protein subunit vaccine containing the COVID-19 spike protein. The vaccine includes three doses.
Last week, during a meeting with former Defense Minister Brigadier General Amir Hatami, Iran’s new Defense Minister Brigadier General Mohammad Reza Ashtiani announced that he plans to enhance the country’s combat power and increase exports of domestic defense products.
Also, previously, Member of the Scientific Committee of Coronavirus Combat and Prevention Mostafa Qaneyee announced that the country is going to produce 3 new coronavirus vaccines next year.
Prior to that, Commander of the Islamic Revolution Guards Corps (IRGC) Major General Hossein Salami said that the home-made anti-coronavirus vaccine is ready to enter the second stage of clinical trial while he was visiting the inauguration of a 64-bed hospital for coronavirus patients in Kerman in Southeastern Iran.
During a ceremony in June in the presence of General Salami, Iran’s Health Minister Saeed Namaki and other Iranian health officials the recombinant Noora vaccine, produced by Baqiyatallah University of Medical Sciences, was put on display.
Baqiyatallah University of Medical Sciences in Tehran works under the supervision of the IRGC. Noora vaccine reached the stage of the clinical trial after 16 months of research work by Iranian scientists.